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Abstract
Background: Sarcoids are peculiar equine benign tumours. Their onset is associated with Bovine Papillomavirus
type -1 or -2 (BPV-1/2) infection. Little is known about the molecular interplay between viral infection and
neoplastic transformation. The data regarding papillomavirus infections in human species show the inactivation of
a number of tumour suppressor genes as basic mechanism of transformation. In this study the putative role of the
tumour suppressor gene Fragile Histidine Triad (FHIT) in sarcoid tumour was investigated in different experimental
models. The expression of the oncosuppressor protein was assessed in normal and sarcoid cells and tissue.
Results: Nine paraffin embedded sarcoids and sarcoid derived cell lines were analysed for the expression of FHIT
protein by immunohistochemistry, immunofluorescence techniques and western blotting. These analyses revealed
the absence of signal in seven out of nine sarcoids. The two sarcoid derived cell lines too showed a reduced signal
of the protein. To investigate the causes of the altered protein expression, the samples were analysed for the DNA
methylation profile of the CpG island associated with the FHIT promoter. The analysis of the 32 CpGs
encompassing the region of interest showed no significative differential methylation profile between pathological
tissues and cell lines and their normal counterparts.
Conclusion: This study represent a further evidence of the role of a tumour suppressor gene in equine sarcoids
and approaches the epigenetic regulation in this well known equine neoplasm. The data obtained in sarcoid
tissues and sarcoid derived cell lines suggest that also in horse, as in humans, there is a possible involvement of
the tumour suppressor FHIT gene in BPV induced tumours. DNA methylation seems not to be involved in the
gene expression alteration. Further studies are needed to understand the basic molecular mechanisms involved in
reduced FHIT expression.
Background
Sarcoids are benign tumours of fibroblastic origin affect-
ing the skin of horses, mules and donkeys and are con-
sidered to be the most common equine cutaneous
neoplasm worldwide [1]. They are histologically charac-
t e r i z e db yd i s o r g a n i z e dd e r m a l proliferation of spindle-
shaped fibroblasts that form whorls and by epidermal
hyperplasia, hyperkeratosis, and rete peg formation [2,3].
The tumours most frequently arise from the skin of the
head, ventral abdomen, legs and the paragenital region
[4]. Sarcoids are locally invasive and often occur at sites
of previous injury or scarring; additionally, they very
rarely regress, more often persist and can be locally
aggressive. Sarcoids may exist as single or multiple
lesions and six clinical types are recognized: occult, ver-
rucous, nodular, fibroblastic, mixed and malignant [5].
Currently there is no effective therapy available for sar-
coids [6].
BPV-1 and less commonly BPV-2 infection is now
recognized as one of the etiological factors of sarcoids.
However, the pathology of this common equine derma-
tological neoplasm is not completely understood. Recent
studies have highlighted the role of the BPV oncogenes
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known about the molecular interplay between viral
infection and neoplastic transformation.
Different Papillomaviruses (PVs), such as Human
papillomavirus type 16 (HPV-16) and BPV-1, seems to
share common processes of infection [10]. Several stu-
dies associate the development of cancer to the loss of
function of a number of tumour suppressor genes. FHIT
is a well characterized tumour suppressor gene involved
in the neoplastic transformation associated to the PVs
infection [11].
The FHIT gene encodes a protein of 147 aa, a diade-
nosine triphosphate hydrolase that cleaves the diadeno-
sine substrate into adenosine diphosphate (ADP) and
adenosine monophosphate (AMP) [12], its physical loca-
tion overlaps with the FRA3B locus, the most active
human common fragile site [13]. FHIT protein is ubi-
quitously expressed in human tissues. Interestingly this
protein is directly involved in tumour suppression inde-
pendently of its hydrolytic activity. It may function as
intracellular and extracellular signalling molecules by
interacting with specific proteins involved in the regula-
tion of proliferative and apoptotic cellular processes
[14-16]. In a variable percentage of cases, depending on
the tumour type, FHIT loss of function is determined by
the hypermethylation status of the associated CpG
island with the consequent repression of gene transcrip-
tion [11]. While alterations in the FHIT gene have been
reported in several human cancers, the putative role of
this tumour suppressor gene and its epigenetic altera-
tion in animal tumours are not well known [17,18]. In
order to obtain new insights into BPV-mediated carci-
nogenesis, we investigated the status of FHIT protein
expression in equine sarcoid cell lines and sarcoid
tumours. Subsequentely, the DNA methylation status of
equine FHIT CpG island spanning the putative promo-
ter was investigated.
Results
FHIT protein expression in sarcoids and cell lines
To gain insights into the molecular mechanisms of
fibroblast transformation in equine sarcoid, we analyzed
tumour samples and sarcoid derived cell lines for the
expression of the FHIT protein. The anti-FHIT polyclo-
nal antibody was used to stain histological sections of 9
BPV positive tumour samples and 1 normal skin sample.
No staining for FHIT protein was observed in 7 out of 9
tumour cases (80%) (Figure 1A, B). Only 2 out of the 9
(20%) sarcoid samples, showed weak intracytoplasmic
immunosignal for FHIT. Fibroblasts of normal skin sam-
ple displayed nuclear and cytoplasmic staining. Normal
blood vessels and sweat glands also stained (Figure 1C).
We also analyzed three equine fibroblast cell lines for
the expression of FHIT protein, one normal and two
derived from sarcoids. By indirect immunofluorescence,
distinct cytoplasmic staining was detected in the normal
equine fibroblast cell line (E-DERM). The immunosignal
was detected only within the cytosol and the pattern
was diffuse. The sarcoid cell lines EqSO1a and EqSO4b
showed very weak cytoplasmic immunofluorescence sig-
nal for FHIT protein as compared with E-DERM (Figure
2). However, EqSO4b cells showed a weaker immuno-
fluorescence staining than EqSO1a. To further confirm
the lack of FHIT protein expression in tumours, three
sarcoid samples, one skin sample from a healthy horse
and the cell lines were analysed by immunoblotting. The
anti-FHIT antibody recognized a band of the expected
molecular weight in the neoplastic tissues, normal skin
and all fibroblast cell lines. An increase in the amount
of FHIT protein level in non-neoplastic skin versus
tumour samples was observed (Figure 3A); moreover
FHIT expression levels were lower in sarcoid cell lines
compared to E-DERM (Figure 3B).
The immunohistochemical and biochemical data indi-
cate that the expression of the FHIT protein is down-
regulated in tumour samples and in fully transformed
sarcoid fibroblast lines.
Figure 1 Expression of FHIT in equine sarcoids and normal
skin. A) FHIT protein is not expressed in neoplastic fibroblasts.
Streptavidin-biotin peroxidase method. Mayer’s haematoxylin
nuclear counterstaining. × 120. B) Neoplastic fibroblasts do not
express FHIT. Streptavidin-biotin peroxidase method. Mayer’s
haematoxylin nuclear counterstaining. × 120. C) FHIT is expressed in
normal skin. Normal fibroblast display cytoplasmic immunosignal.
Normal blood vessels and sweat glands also stain. Streptavidin-
biotin peroxidase method. Mayer’s haematoxylin nuclear
counterstaining. × 240.
Figure 2 Immunofluorescence-mediated detection of FHIT
protein in E-DERM and sarcoid derived cell lines. A) E-DERM
normal fibroblasts show cytoplasmic staining X120. B) Fully
transformed fibroblasts from EqSO1a show faint cytoplasmic
staining X120. C) Fully transformed fibroblasts from EqSO4b show a
very faint cytoplasmic staining. X120.
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GenBank search for equine FHIT gene sequences gave
the predicted coding sequence from the ATG to the
stop codon [XM_001490610]. To obtain the putative
regulatory region sequence of the equine FHIT locus,
the human FHIT CpG island sequence [U76263] was
used to query genomic databases. This sequence encom-
passes the region of the non coding exon 1 and the par-
tial intron 1 and represents the region analysed in
human cancers for differential methylation profile. The
U76263 human sequence was compared, through the
BLAT algorithm of the UCSC genome browser, with the
Horse Sep. 2007 (Broad/equCab2) Assembly.
The region (573 bp) showed 87% similarity with the
human sequence. The correct localization of the CpG
island and the co-linearity of the UTR sequence with
the FHIT coding sequence were confirmed through
direct sequencing of PCR fragments obtained using
respectively genomic DNA and cDNA as templates.
These analyses were performed in E-DERM cell line.
The analyses of the PCR fragments amplified using
cDNA as template, showed the presence of two different
transcripts. The analysis of these sequences through the
BLAT algorithm revealed the presence of 4 exons in iso-
form 1 and 5 exons in isoform 2. The additional exon of
isoform 2 (exon 4) is 145 bp long. Figure 4A shows the
5’ FHIT transcript organisation in the horse genome.
The equine FHIT 5’UTR region organization is compar-
able with the data deriving from other species such as
Bos [17]. The DNA sequences of both transcripts have
been deposited in GenBank [JN403048, JN403049].
Equine FHIT CpG island methylation analysis in sarcoid
tissues and cell lines
Sarcoid samples were investigated for the DNA methyla-
tion profile of the CpG island associated to the putative
regulative region.
The CpG island sequence includes 32 CpG dinucleo-
tides, and the region analysed corresponds to the CpG
island predicted with the CpGplot analysis. It is slightly
larger then the region analysed in human and bovine
tumours [17]. Figure 4B shows the equine CpG island
and the position of the amplification primers obtained
through the MethPrimer algorithm. The bisulfite DNA
conversion and the subsequent cloning and sequencing
analysis were performed also for a BPV negative normal
skin sample. For all samples at least 10 clones were
sequenced. The extensive analysis of all CpG dinucleo-
tides present in the region, showed only some random
differentially methylated position in comparison with
the normal control (Additional file 1: Figure S1). Similar
results were also obtained extending the DNA methyla-
tion analysis to the sarcoid cell lines, EqSO1a and
EqSO4b compared to the E-DERM fibroblast cell lines.
Discussion
Sarcoids account for an high percentage of all equine
neoplasms and are the most common tumour diagnosed
in horses [1]. Few studies have been carried out so far
concerning the molecular mechanisms underlying
equine sarcoids carcinogenesis. It is well known that
BPV is involved in the pathogenesis of the sarcoid, and
the role of its oncoproteins in the carcinogenic process
has been recently clarified [19,20], however little is
known about the molecular relationship between viral
infection and neoplastic transformation. Recently, Yuan
et al. [21], have described the upregulation of MMP-1
and AP1 in sarcoid, underlying the invasivity potential
of such tumour. To identify the key molecules in these
phenomena and on the basis of the data deriving from
other species, we analysed the role of the tumour sup-
pressor FHIT gene. FHIT is a tumour suppressor gene
and many lines of evidence support the association
between HPV infection and FHIT expression alteration
in different cancer types [22,23]. However, FHIT
Figure 3 Western blotting analysis of FHIT protein in sarcoid
tissues and sarcoid derived cell lines. A) The expression of FHIT
is reduced in sarcoids (S1, S2 and S3) compared to normal skin
sample (N). B) FHIT protein expression in EqSO1a and EqSO4b in
comparison with E-DERM. The lower blot shows actin expression to
demonstrate the same amount of protein loaded on the gel. Figure 4 Equine FHIT genomic locus organization.A )T h e
organization of the 5’UTR of the FHIT transcript is shown; the
shaded box represent the exon present only in the isoform 2. B)
The FHIT CpG island is reported according the MethPrimer software
scheme and the bisulfite primer positions are also shown.
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bovine urinary bladder tumours which are composed of
both epithelial and vascular (i.e. mesenchymal) tumours
(personal observations).
In this study we have characterized the expression of
FHIT protein by examining it in a normal fibroblast cell
line (E-DERM) and fully transformed sarcoid fibroblast
lines explanted from equine sarcoid tumours (EqSO1a
and EqSO4b), as well as in normal skin and sarcoid tis-
sues. The data we obtained document, for the first time,
a reduction of FHIT protein expression in in vitro
model of sarcoid-derived cell lines as well as in naturally
occurring tumours. The consistency of data between in
vivo and in vitro systems strenghten the validity of such
cell culture system for gene expression analysis.
Our data indicate that FHIT protein is expressed in
normal fibroblasts, whereas it is much reduced in both
in vivo and in vitro tumours. It is worthwhile noting
that EqSO4b has lower level of the protein compared to
the EqSO1a. The EqSO4b cell line contains higher levels
of viral genome and viral oncoprotein transcripts than
EqSO1a [24]. We may speculate that altered expression
of FHIT protein may correlate with viral load and/or
viral oncogenes expression. However, further studies are
needed to clarify this point. Sarcoids may exist as six
different clinical types [5]; although we have examined a
limited number of samples, we suggest a lack of correla-
tion between down-regulation of FHIT expression and
clinical appearance, indicating a common mechanism
underlying the reduction of protein expression acting
early during the development of equine sarcoids.
Our results are in agreement with several previous
studies indicating that the loss of FHIT expression is
frequent in a variety of tumors [25,26] above all in PVs
induced cervical lesions [11,22,27,28]. Lowered levels of
the FHIT protein were also documented in pagetoid
variant of BPV induced urothelial tumour [18].
Promoter methylation is the primary epigenetic altera-
tion associated with transcriptional silencing of tumour
suppressor genes during tumorigenesis [29-32]. To
determine the reasons for diminished FHIT expression
in sarcoid tumour we performed the analysis of the
methylation status of the FHIT 5’-CpG island. Our data
indicated that FHIT gene promoter hypermethylation
did not occur either in sarcoid tissues or in sarcoid
derived cell lines, suggesting that this epigenetic
mechanism may be not involved in FHIT aberrant
expression in sarcoids. This is in accordance with a pre-
vious paper documenting no aberrant methylation caus-
ing FHIT promoter silencing in BPV induced vesical
tumors of cattle [17]. It is reasonable to assume that
BPV does not alter the methylation status of FHIT pro-
moter. It is worth noting that similar data have been
obtained both in vitro and in vivo, thus again validating
the sarcoid derived cell lines as a good model for the
study of sarcoids [24]. Our data show the presence of an
alternative splicing of equine FHIT transcript in 5’UTR
region; this is consistent with the data obtained in other
species such as human and bovine [17], in which several
different 5’UTR regions were described. A well-known
regulatory role has been described for the 5’ and 3’ UTR
region in mammalian genome [33]. The complex struc-
ture of the 5’UTR region of FHIT locus may suggest
that this region might be target of post-transcriptional
regulative mechanism.
In human species the mutational analysis of FHIT
indicates the potential role of other mechanisms such as
point mutation and deletions, with loss of heterozigosity
(LOH). The human FHIT gene encompasses the FRA3B
fragile site, a common target of genetic alterations [34].
This locus is a hot spot for early inactivation in carcino-
gen-exposed tissue [13,35]. FRA3B fragile site is also
reported to be the site for HPV-16 integration and
demonstrated to undergo frequent LOH in cervical car-
cinoma [36]. Different PVs, such as HPV-16 and BPV-1,
seems to share common processes of infection [10]. We
speculate that the involvement of BPV infection in
equine tumorigenesis may be related with FHIT LOH,
but this issue needs further investigation.
Our findings suggest an association between BPV
infection and FHIT protein expression alteration raising
t h ep o s s i b i l i t yo fam e c h a n i s t i cr o l ef o rt h eF H I Tg e n e
as a cofactor with BPV in triggering the development of
equine sarcoid tumour.
Conclusions
Biochemical and immunohistochemical analyses suggest
that FHIT protein is often reduced in sarcoid tissues
and cell lines. The epigenetic analysis suggest that
altered DNA methylation is not associated with the
altered expression of the FHIT protein. While further
studies are needed to clarify the molecular mechanisms
for FHIT protein downregulation, we suggest that this
tumour suppressor gene is an important player in sar-
coid transformation.
Methods
Tumour Samples
Samples of equine sarcoid (N°9) were derived from the
archives of the Department of Pathology and Animal
Health, University of Naples “Federico II”.N o r m a ls k i n
from healthy horses was also examined. Formalin-fixed
paraffin embedded tissue was available from each case.
Sections taken from these blocks and stained by Haema-
toxylin and eosin (HE) were re-evaluated to confirm the
diagnosis. The 9 samples were derived from 9 different
animals. All sarcoids were known to be positive for BPV
DNA [9].
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were also collected and immediately frozen at -80°C for
biochemical analysis.
Cell cultures
E-DERM fibroblast cell lines, derived from horse dermis,
were obtained from the American Type Culture Collec-
tion. EqSO1a and EqSO4b sarcoid derived cell lines
have been previously described [24]. All cells were main-
tained in culture in DMEM (Dulbecco’s modified eagle
medium) supplemented with 10% FBS (Gibco) in a 37°C
humidified atmosphere of 5% CO2 in air.
Immunohistochemistry
Nine sarcoid samples and one normal skin sample were
stained. Briefly, paraffin sections were deparaffinized,
and blocked for endogenous peroxidase in 0.3% H2O2 in
methanol for 20 min. Antigen enhancement was per-
formed by pretreating with microwave heating (twice for
5 min each at 525 W). The anti-FHIT antibody (Santa
Cruz, USA) was applied at 1:100 dilution overnight at
room temperature in a humified chamber. The slides
were washed three times with phosphate-buffered saline
(PBS), then incubated with appropriate secondary anto-
bodies as previously reported [37]. Sections were washed
three times with PBS and then incubated with streptavi-
din-conjugated to horseradish peroxidase (LSAB Kit;
DakoCytomation, Denmark). Colour development was
obtained by treatment with diaminobenzidine (DakoCy-
tomation, Denmark) for 5 min. Sections were counter-
stained with Mayer’s haematoxylin. In the
corresponding negative control section, the primary
antibodies were either omitted or replaced with appro-
priate normal sera.
The scoring of the immunoreactivity was determined
in a ‘blind’ s t u d yb yt w oo b s e r v e r s( G Ba n dA C ) .T h e
intensity of labelling in each specimen was scored from
absent to very strong immunosignal.
Immunofluorescence and confocal laser-scanning
microscopy
E-DERM, EqSO1a and EqSO4b cell lines were grown for
2 days on coverslips, washed with PBS, fixed in 4% par-
aformaldehyde for 20 min, permeabilized with 0,1% tri-
ton X-100 in PBS 5 min. The slides were blocked with
2% BSA for 30 min. The anti-FHIT primary antibody
was applied O/N at 4°C in a humified chamber at 1:50
dilution and after washing with PBS, incubated with
Alexa Fluor 546 goat anti-rabbit 30 min at RT (Molecu-
lar Probes. Leiden, The Netherlands).
Finally, after washing with PBS, the slides were
mounted in aqueous medium PBS:Glycerol 1:1 (Sigma,
Milan, Italy). For scanning and photography, a confocal
laser-scanning microscope LSM-510 (Zeiss, Gottingen,
Germany) was used. Alexa Fluor 546 was irradiated at
543 nm and detected with a 560 nm bandpass filter.
Protein extraction and SDS PAGE/Western blotting
Three fresh tumour (S1, S2 and S3) and one sample of
normal skin (N) were available for molecular analysis.
These were snap frozen in liquid nitrogen and homoge-
nized in ice-cold lysis buffer (50 mM Tris pH7.5; 150
mM NaCl; 1 mM EDTA; 0.25% Deoxicolic acid, 1% Tri-
ton X100) added with 20 mM sodium pyrophosphate,
0.1 mg/ml aprotinin, 2 mM phenylmethylsulphony
fluoride (PMSF), 10 mM sodium orthovanadate
(Na2VO3), and 50 mM NaF.
Cell lines were grown for 2 days in 60-mm dishes,
washed with ice-cold phosphate saline buffer two times
and lysed for 20 minutes in ice-cold lysis buffer. Tissue
homogenates and cell lysates were clarified by centrifuga-
tion, and the quantity of proteins was determined by use
of a protein assay kit (Bio-Rad Laboratories, Milan, Italy).
50 μg of total protein were boiled and fractionated in
15% SDS-PAGE gel. The proteins were blotted from the
gel onto nitrocellulose membranes. The membranes were
blocked with 5% non-fat dry milk in TBS buffer at room
temperature, washed with TBS-0.1% Tween and incu-
bated with anti-FHIT antibody at dilution 1: 500 (Santa
Cruz). After appropriate washing steps, peroxidase-con-
jugated anti-rabbit IgG (Amersham Pharmacia Biotech)
were applied for 1 hour at 1:5,000. After washing, bound
antibody was visualized on ECL film (Amersham Phar-
macia Biotech). The blots were stripped and reprobed
against mouse anti-actin antibody (Calbiochem) at
1:5,000 to confirm equal loading of proteins in each lane.
Bioinformatic web tools for sequence analyses and
primer design
NCBI Genbank http://www.ncbi.nlm.nih.gov/sites/entrez
to obtain specific sequence; UCSC BLAT http://genome.
ucsc.edu/cgi-bin/hgBlat to obtain the sequence of non-
coding regions and to recovery and compare the
sequences of different species. BLAST algorithm http://
blast.ncbi.nlm.nih.gov/ to identify the more informative
sequences, to compare the horse specific nucleotidic
sequences with that of other species; EMBOSS
CpGPlot/CpGReport/Isochore http://www.ebi.ac.uk/
Tools/emboss/cpgplot/ for the analysis of the CpG con-
tent; MethPrimer to design primers for methylation ana-
lysis http://www.urogene.org/methprimer/index1.html;
Primer3 http://primer3.sourceforge.net/ and NCBI pri-
mer-blast http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi to design PCR primers.
Cell lines DNA and RNA extraction
Genomic DNA was extracted from one 60-mm dish
respectively of E-DERM, EqSO1a and EqSO4b cell lines
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protocol (Promega Corporation, USA). The purified
DNA was resuspended in TE.
Total RNA was extracted from E-DERM, EqSO1a and
EqSO4b cell lines. The cell pellet derived from two 60-
mm dishes, cultured as described above, was resus-
pended in 1 ml of Trizol (Invitrogen, Carlsbad, CA,
USA). The RNA purification was obtained according to
the Trizol protocol.
PCR and RT-PCR analyses
The equine specific FHIT CpG island was obtained by
genomic DNA PCR amplification with the following pri-
mers: FHITCpGF TCCTGAGAGGGACAGTGGTT,
FHITCpGR GGGGAGGGTTAGGGTGAG. The purified
PCR product (573 bp) was directly sequenced by the dye
terminator method (PRIMM Facility, Naples, Italy).
For all cell lines, cDNA was prepared, after DNAaseI
RNAase free digestion, using 1 μg of total RNA accord-
ing to the protocol of Quantitect Reverse Transcription
for RT-PCR (Qiagen, Germany). The final volume was
20 μl. cDNA quality was tested through the amplifica-
tion of the housekeeping gene GAPDH. The PCR pri-
mer sequences were GAPDHF
GCCATCACCATCTTCCAG and GAPDHR
GTTCACGCCCATCACAAAC and the PCR product
lenght was 192 bp. The FHIT specific primers used
were the following: FHITF2 GTCGGGAATTG-
TAGTCCTC, FHITF3 CTCTCTTCCCGGGTCTGTAA
and FHITR2 GTTCACGAGGGCAAAGGATA. The F2
R2 product lenght was 359 bp; the F3 R3 product lenght
was 451 bp. The purified PCR products were directly
sequenced by the dye terminator method (PRIMM Facil-
ity, Naples, Italy).
DNA extraction from paraffin-embedded sarcoid samples,
bisulfite conversion and sequencing
Genomic DNA was isolated from paraffin-embedded
sections using standard procedures and was precipitated
with 250 mM NaCl and isopropanol. Extracted DNA
(0.25 - 1 μg) was bisulfite-converted using the EpiTect
Bisulfite Kit (Qiagen, Germany), according to the proto-
col relative to the paraffin embedded samples. Samples
were eluted in a final volume of 20 μl. To study the dif-
ferential methylation status of FHIT putative promoter,
bisulfite sequencing was performed. Briefly, 1 μlo f
bisulfite-converted DNA was amplified using a double
step PCR (semi-nested PCR) carried out using Gradient
PCR Express (Hybaid, Middlesex, UK). Step 1 primer
sequences are: bisFHITF1 TTTTTTGAGAGGGA-
TAGTGGTTTT and bisFHITR1 ACCAATACT-
CAAAAATAAACCCTCA; step 2 primer sequences are:
bisFHITF2 GTTATTATGGTTTTTGATTGGGTTG
and the above cited bisFHITR1. The second
amplification was carried out using 1 μl of first amplifi-
cation product as template. The thermal cycling condi-
tions were: 95°C for 3 min, followed by 95°C for 30 sec,
52°C for 45 sec and 72°C for 45 sec for 25 (first amplifi-
cation) or 35 (second amplification) cycles. After ampli-
fication, PCR products were recovered from agarose gel
using QIAquick Gel Extraction Kit (Qiagen), following
manufacturer’s instructions. Purified PCR products were
cloned in the pGEMeasy cloning vector (Promega Cor-
poration, USA). After cloning, DNA fragments were
sequenced by the dye terminator method (PRIMM Facil-
ity, Naples, Italy).
Additional material
Additional file 1: Figure S1. Bisulfite sequencing of equine FHIT CpG
island. In the top are summerised the CpG island (boxed) and the
position of primers of the nested PCR. Circles below indicate methylation
status: filled circles, methylated CpGs; open circles: unmethylated CpGs.
Each row of circles corresponds to one clone. The number on top of
circle is referred to CpG position and the column on the left is referred
to number of indipendent clones sequenced.
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